Literature DB >> 24411065

Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.

Christine Serratrice1, Monia Bengherbia2, Marine Alessandrini3, Bernard Grosbois4, Fabrice Camou5, Yves Marie Pers6, Michael Bismuth7, Isabelle Marie8, Nadia Belmatoug2, Marc Berger9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24411065     DOI： 10.1016/j.bcmd.2013.12.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN： 1079-9796            Impact factor:   3.039


× No keyword cloud information.
  1 in total

1.  Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.

Authors:  Derralynn A Hughes; Derlis E Gonzalez; Elena A Lukina; Atul Mehta; Madhulika Kabra; Deborah Elstein; Isaac Kisinovsky; Pilar Giraldo; Ashish Bavdekar; Thomas N Hangartner; Nan Wang; Eric Crombez; Ari Zimran
Journal:  Am J Hematol       Date:  2015-07       Impact factor: 10.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.